Solid Biosciences SLDB 深 沪
已收盘 12-12 16:00:00 美东时间
5.87
0.000
0.00%
华盛通- 最 高6.04
- 今 开5.88
- 成交量 64.83万股
- 最 低 5.79
- 昨 收 5.87
- 总市值 4.57亿
- 52周最高 7.37
- 市盈率 静 --
- 换手率 0.83%
- 52周最低 2.41
- 委 比 -52.27%
- 总股本 7786.91万
- 历史最高 822.60
- 量 比 0.73
- 振 幅 4.26%
- 历史最低 1.81
- 每 手 1
- 风险率 1.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
Solid Biosciences Inc. announced it will present data on its next-generation AAV-SLB101 capsid and cardiac gene therapy pipeline at the Global CardioVascular Clinical Trialists Forum. Dr. Gabriel Brooks, the company’s Chief Medical Officer, will deliver two presentations, lead a panel discussion, and exhibit a poster. Dr. Nicolas Christoforou, Head of Discovery and Translational Development, will also present on preclinical research for CPVT gene...
12-08 13:00
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. granted 23,284 restricted stock units (RSUs) to two newly hired employees. The RSUs vest annually over four years, contingent on continued employment. The grant was made under the Company’s 2024 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). Solid Biosciences focuses on developing precision genetic medicines for rare neuromuscular and cardiac diseases, with a diverse pipeline of gene the...
12-01 21:05
Solid Biosciences Announces The FDA Grants Rare Pediatric Disease Designation For SGT-212, Its Investigational Gene Therapy For Friedreich's Ataxia
Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it received Rare Pediatric
12-01 21:02
Solid Biosciences Announces Non-Exclusive Worldwide License And Collaboration Agreement With Andelyn For Use Of Solid's Proprietary, Next-Gen Capsid, AAV-SLB101
- Non-exclusive license providing Solid's proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) --
11-17 21:13
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. announced its participation in two upcoming investor conferences. Bo Cumbo, President and CEO, and Gabriel Brooks, MD, Chief Medical Officer, will participate in fireside chats at the Jefferies Global Healthcare Conference in London on November 18, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. Live webcasts and replays will be available on the Company’s website.
11-11 13:00
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Chardan Capital Maintains Buy on Solid Biosciences, Maintains $15 Price Target
Chardan Capital analyst Geulah Livshits maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $15 price target.
11-04 21:31
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. has granted 26,550 restricted stock units (RSUs) to two newly hired employees. The RSUs vest over four years, contingent on continued employment. This grant was made under the Company’s 2024 Inducement Stock Incentive Plan to incentivize the employees to join the company. Solid Biosciences focuses on developing gene therapies for rare neuromuscular and cardiac diseases, aiming to improve the lives of patients with devastati...
11-04 21:05
